ArticleCurrent protocols2026
Rapid, Scalable, and Cost-Effective Manufacturing of Uniform Non-Enveloped, Tag-Free Virus-Like Particles.
Article in Current protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rapid, Scalable, and Cost-Effective Manufacturing of Uniform Non-Enveloped, Tag-Free Virus-Like Particles.Current protocols · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus-like particles (VLPs) are widely recognized as safe and versatile nanostructures with broad applications in vaccine development, gene delivery, and nanotechnology, but their production typically requires time-consuming procedures, incurs high costs, and yields products of limited purity. This article outlines a rapid, scalable, and cost-effective method for producing high-quality VLPs using the VP1s capsid protein from murine polyomavirus. The procedure comprises four principal stages: expression of the capsid protein in Escherichia coli, extraction and stabilization of the protein, purification to yield high-quality capsomeres, and controlled in vitro assembly of VLPs. Compared with conventional protocols that rely on in vivo assembly and labor-intensive purification procedures, such as ultracentrifugation- or affinity tag-based methods, the described approach provides a streamlined and rapid workflow that avoids affinity tags, achieves consistently high yields, and enables precise regulation of assembly conditions, resulting in a scalable and highly cost-efficient strategy for VLP production within 5 days. © 2026 Wiley Periodicals LLC. Basic Protocol 1: Expression and preparation of polyomavirus VP1 protein in E. coli Basic Protocol 2: Polymomavirus VP1 purification Basic Protocol 3: VP1 assembly Basic Protocol 4: Quality control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.